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Background. We aimed to test a mindfulness-based psychoeducation group (MBPEG), v. a conventional psychoeduca-
tion group (CPEG) v. treatment as usual (TAU), in patients with schizophrenia-spectrum disorders over a 24-month
follow-up.
Method. This single-blind, multi-site, pragmatic randomized controlled trial was conducted in six community treatment
facilities across three countries (Hong Kong, mainland China and Taiwan). Patients were randomly allocated to one
of the treatment conditions, and underwent 6 months of treatment. The primary outcomes were changes in duration
of re-hospitalizations and mental state (Positive and Negative Syndrome Scale; PANSS) between baseline and 1 week,
and 6, 12 and 18 months post-treatment.
Results. A total of 300 patients in each country were assessed for eligibility between October 2013 and 30 April 2014,
38 patients per country (n = 342) were assigned to each treatment group and included in the intention-to-treat analysis.
There was a signiﬁcant difference in the length of re-hospitalizations between the three groups over 24 months (F2,330 =
5.23, p = 0.005), with MBPEG participants having a shorter mean duration of re-hospitalizations than those in the other
groups. The MBPEG and CPEG participants had signiﬁcant differential changes in proportional odds ratios of complete
remission (all individual PANSS items <3) over the 24-month follow-up (37 and 26%, respectively), as opposed to only
7.2% of the TAU group (χ2 = 8.9 and 8.0, p = 0.001 and 0.003, relative risk = 3.5 and 3.1, 95% conﬁdence interval 2.0–7.2 and
1.6–6.3).
Conclusions. Compared with TAU and CPEG, MBPEG improves remission and hospitalization rates of people with
schizophrenia spectrum disorders over 24 months.
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Introduction
Schizophrenia is a severe mental disorder with a global
12-month prevalence of 1.1–1.8% of adult populations
(Global Burden of Disease Study 2013 Collaborators,
2015). Antipsychotic medications are evidenced to
reduce positive symptoms but cannot signiﬁcantly
improve functioning, risk of relapse and residual
symptoms of most psychotic patients (Bhagyavathi
et al. 2015; Schennach et al. 2015). According to recent
practice guidelines (Lehman et al. 2004; National
Institute for Health and Care Excellence, 2014), psycho-
social interventions such as psychoeducation and other
similar programmes can improve patient outcomes
when used in adjunct to antipsychotic pharmacother-
apy. A combination of medications and psychosocial
interventions for people with early psychosis has
been shown to improve these patients’ functioning
and quality of life, as well as to reduce their risk of
relapse, when compared with pharmacological treat-
ment alone (Guo et al. 2010).
Systematic reviews of psychoeducation interven-
tions for schizophrenia show that the intervention
when delivered in both one-to-one and group sessions
signiﬁcantly reduces relapse rates and improves levels
of medication adherence (Xia et al. 2011). However,
many psychoeducation intervention programmes
for people with schizophrenia do not incorporate
adequate strategies for empowering self-management
of the illness and pay scant attention towards facilitat-
ing an acceptance of the illness and the distressing
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experiences of symptoms (Bäuml et al. 2006; Chadwick
et al. 2009).
Mindfulness-based stress reduction (MBSR) pro-
grammes consist of approaches that aim to facilitate
patients’ acceptance, and are focused on reducing dis-
tress by changing negative thoughts, emotions and
attitudes towards the illness (Chadwick et al. 2009;
Chien & Lee, 2013). Research evidence regarding the
effectiveness of MBSR on stress and illness manage-
ment in patients with depression and anxiety is proliﬁc
and well established (Ma & Teasdale, 2004). Standard
biweekly 10-session MBSR programmes for severe
depression and anxiety are evidenced to empower
patients’ self-care and symptom management, improve
insight and enhance control over distressing thoughts
(Ma & Teasdale, 2004; Chlesa & Serretti, 2011). The
beneﬁts of mindfulness-based interventions (MBI)
have also been evidenced in the treatments of a wide
variety of physical and mental disorders (Pull, 2009;
Chlesa & Serretti, 2011). It has been suggested that
the positive effects of MBI in major depression could
be attributed to reductions of over-general memory
and ruminative thinking, and improvements in meta-
awareness leading to an overall decrease in depression
severity (Williams et al. 2000). The ﬁndings of other
similar studies in depressive/anxiety disorders also
suggested that MBI training could enhance patients’
ability to reﬂect upon previous crises in a decentred
manner, which helps to relate differently to earlier dis-
tressing experiences in order to prevent future relapse
(Kingston et al. 2007; Hargus et al. 2010).
The approach could be particularly useful in schizo-
phrenia spectrum disorders as they are often partially
responsive to current treatments; resulting in frequent
relapses with associated high societal and economic
burden (Chlesa & Serretti, 2011). However, research
into the effectiveness of MBI as treatments for psych-
otic disorders is still in its relatively early stages. Two
recent feasibility trials (Freeman et al. 2002; Chadwick
et al. 2009) with short follow-up suggested that there
might be beneﬁts from MBI (eight to 10 biweekly ses-
sions) for psychosis in terms of improving illness man-
agement and preventing relapses, and another recent
single-site controlled trial in Hong Kong (Chien &
Lee, 2013) found that a mindfulness-based psychoedu-
cation programme for 36 patients with schizophrenia
resulted in signiﬁcant improvements in insight into
the illness, functioning and symptom severity over
a longer-term follow-up. An earlier meta-analysis
(Khoury et al. 2013), including 13 studies with 468
patients with psychotic disorders, found an overall
moderate effect of MBI on symptom severity and
relapse rate in single-group pre- and post-test studies,
and a small to moderate effect in studies using a com-
parison group. Our recent systematic review of MBI for
schizophrenia (Lam & Chien, 2016) identiﬁed six eli-
gible randomized controlled trials (RCTs) which
described beneﬁts in schizophrenia (i.e. improvements
in global functioning, emotional regulation and relapse
prevention). Because of variation in study designs, out-
come measures and interventions, further RCTs are
needed in order to be conﬁdent of the positive effects
of MBI for diverse samples with schizophrenia spec-
trum disorders. Therefore, these preliminary ﬁndings
suggest that a multi-site RCT with a larger sample
and active comparison group and longer follow-ups
is required in order to robustly test the efﬁcacy of
MBI for schizophrenia.
To the best of our knowledge, this is the ﬁrst inter-
national multi-site study testing a mindfulness-based
psychoeducation group (MBPEG) programme for
out-patients with schizophrenia spectrum disorders.
We hypothesized, on the basis of accumulating evi-
dence (Ma & Teasdale, 2004; Kingston et al. 2007;
Chadwick et al. 2009; Chlesa & Serretti, 2011; Chien
& Lee, 2013), that the effect of MBPEG in addition
to treatment as usual (TAU) would result in signiﬁ-
cantly greater improvement of patients’ primary out-
comes (re-hospitalizations and symptoms), as well as
insight into illness/treatment and functioning over a
24-month follow-up, when compared with those in a
conventional psychoeducation group (CPEG) pro-
gramme or TAU alone.
Method
Trial registration
This trial was prospectively registered at ClinicalTrials.
gov (NCT01667601) (https://clinicaltrials.gov/ct2/show/
NCT01667601).
Study design
The study was a single-blind multi-centre RCT with a
three-group repeated-measures design comparing the
treatment outcomes of out-patients with schizophrenia
spectrum disorders. The study was approved by the
Human Subjects Research Ethics Committee at The
Hong Kong Polytechnic University (HSEARS2012
11001) and the clinics under study.
Participants
Patients were recruited from and assessed at psychi-
atric out-patient clinics in Hong Kong, Taiwan and
China (i.e. two clinics in each country). At recruitment,
about 1000 patients with schizophrenia spectrum
disorders were attending the clinics in each country.
Inclusion criteria for participants from the six
clinics were: age 18–64 years; current Diagnostic and
2082 W. T. Chien et al.
https://doi.org/10.1017/S0033291717000526
Downloaded from https://www.cambridge.org/core. Fromageries Bel, on 08 Feb 2018 at 14:48:40, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Statistical Manual of Mental Disorders (DSM-IV) diag-
nosis of schizophrenia and other psychotic disorders as
ascertained by the Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I) (First et al. 2001);
having 45years of illness at recruitment; and able to
understand Chinese/Mandarin. Exclusion criteria were:
having co-morbidity of another mental illness such as
affective and organic brain disorders; moderate or
severe learning disability; and receiving mindfulness
and/or other psychotherapies in the past 2 years. All
patients provided their voluntary written informed
consent to participate after receiving a full description
of the study.
Randomization and masking
The consenting patients were listed in alphabetical
order of their surnames, each was assigned a
unique study number and 114 (48–55%) from each
country were then selected randomly from the lists,
using computer-generated random numbers (using
www.random.org) by an independent statistician.
Following baseline measurement at the clinics, ran-
domization to a 6-month course of MBPEG plus
TAU, CPEG plus TAU, or TAU alone (38 patients per
treatment group per country) was conducted by an
independent statistician off-site using a stochastic
minimization program to balance the gender, severity
of psychotic symptoms [scores of all items of Positive
and Negative Syndrome Scale (PANSS) 43, total
score of 60–150, or total score of +120] (Bell et al.
1992), and medication adherence (poor or satisfactory
on the Adherence Rating Scale) (Coldman et al. 2002)
(see Fig. 1 for the ﬂow of participants in the study).
To minimize potential contamination of treatment
effects, or subject biases, participants were asked not
to reveal their study participation to clinical staff or
discuss the contents of their programme with other
patients in the clinics who were not in their treatment
group. The participant lists were also concealed from
the clinic staff and researchers over the duration of
the study. The outcome assessor and clinic staff were
blinded to treatment allocation.
Procedures
Participants (n = 114) received a 24-week (12 biweekly,
2-h sessions) MBPEG, consisting of 10–12 patients
per group. The MBPEG was based on Kabat-Zinn’s
MBSR programme modiﬁed for Chinese psychotic
patients in Hong Kong (Chien & Thompson, 2014),
as well as the recent psychoeducation programme by
Chan et al. (2009). One of the six trained psychiatric
advanced practice nurses (average clinical and mind-
fulness training experiences: 8 to 10 and 2 to 3 years,
respectively) worked with patients to help them
become increasingly aware of and relate differently to
their thoughts, feelings, perceptions and physical sen-
sations, as opposed to understanding them as being
accurate readouts on reality. The mindfulness theory
employed in MBPEG assumes that, in patients with
psychotic disorders, a lack of insight into the illness
and its treatment and inability of accepting and/or
resolving the illness-related problems, together with
poor psychosocial functioning, impair help-seeking
and illness management behaviours. The MBPEG is
designed to gradually increase patients’ insight into
and acceptance of their illness, and be motivated to
control their psychotic symptoms and actively engage
with their treatment plans. The programme consisted
of seven domains in three phases (see Table 1).
Individual participants were requested and encour-
aged to perform regular (at least twice daily) practices
of focused awareness of thoughts, feelings, bodily sen-
sations and mindful breathing and walking in the early
stages; and then, they were facilitated to establish self-
empowering and constructive outlooks for working
with distressing, or negative thoughts and feelings.
The MBPEG adopted some additional speciﬁc strat-
egies to address commonly held Chinese cultural atti-
tudes. During the ﬁrst phase, the group sessions
focused on understanding their strong interdepend-
ence, encouraging better problem-solving and mutual
support between group members. Within the second/
third phases, participants were encouraged to cultivate
an open and accepting attitude and positive responses
to life events or problems and to develop a ‘decentred’
(i.e. passing events in mind) attitude on their thoughts
or related feelings (Ma & Teasdale, 2004; Chien & Lee,
2013). During the later sessions, they were supported
to explore the strong self-centredness that is tradition-
ally common in some Chinese cultural groups (e.g.
‘saving face’ and self-blame) and accordingly recon-
struct their self-image and perception.
Similar to the MBPEG, the CPEG (n = 114) consisted
of 12 bi-weekly 2-h sessions (10–12 participants per
group), which was based on previously developed
group psychoeducation manuals (Macpherson et al.
1996; Chien & Bressington, 2015). Participants received
psychosocial support and psychoeducation from one
of three psychiatric nurses trained by the research
team and one psychotherapist within a 3-day work-
shop. The trained psychiatric nurses were already
well experienced in facilitating psychiatric rehabilita-
tion and education groups (average years of working
in psychiatric rehabilitation services: 7.5 years). CPEG
comprised of four stages: joining with individual
patients and families (two sessions, focusing on orien-
tation and engagement of participants and discussion
about their goals and action plans for illness manage-
ment); an education and survival skills workshop
Mindfulness-based psychoeducation group programme for people with schizophrenia 2083
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Fig. 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of clinical trial for two treatment and usual-care
groups. OPC, Out-patient clinic; PANSS, Positive and Negative Syndrome Scale; SLOF, Speciﬁc Level of Functioning
Scale; SSQ6, six-item Social Support Questionnaire; ITAQ, Insight and Treatment Attitudes Questionnaire; ITT,
intention-to-treat.
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Table 1. Mindfulness-based psychoeducation programme for people with schizophrenia
Phase Component Goals or rationale Main topics/themes Practice
I. 1. Orientation and engagement
(two sessions)
a. Establishment of mutual trust and respect,
treatment goals and objectives, and expected
roles and responsibilities in the group; and
b. Understanding of the group programme and
information about the illness and its
symptoms
• Orientation to the MBPEG and its
functions
• Establishing trust and respect among
group members
• Achieving agreed goals and objectives
• Schizophrenia and its impacts
i. Self-introduction and game activities
ii. Group discussion about their roles and
responsibilities in the group, and about
schizophrenia and its impacts on patients
and their families
2. Focused awareness of bodily
sensations, thoughts, feelings
and symptoms (three sessions)
Session 1: Stepping out of automatic pilot and
negative thoughts
Rationale:
a. Mindfulness starts when we recognize the
tendency to be on automatic pilot;
b. Commitment to learning how to step out of it
and being aware of each symptom and
related experience; and
c. Practice in purposefully drawing attention to
bodily sensations and movements
• Body scan, noticing sensations, feelings
and thoughts
• Dealing with barriers to focusing
thoughts, emotions and events,
particularly pleasurable events
i. Body scan
ii. Breath and awareness and mindfulness
thereof
iii. Focusing on both pleasant and annoying
events
iv. Focused awareness of the body, thoughts
and feelings (homework)
Session 2: Mindfulness of the breath and staying
present
Rationale:
a. Becoming familiar with the behaviour of the
mind (often being busy and scattered);
b. The mind is most scattered when trying to
cling to something and avoid others; and
c. Mindfulness offers a means to stay present by
providing another place from which to view
things
• Awareness of the breath offers an anchor
to the present (a possibility of being more
focused and gathered)
• Categorizing experiences v. describing
bare sensations/thoughts
• Getting to know the territory of
schizophrenia
i. Seeing/hearing and intentional awareness of
breath, body, sounds and thoughts
ii. 3-min breathing space (awareness of body,
re-directing and expanding attention),
opening (controlling breath)
iii. Stretching and breathing (homework)
iv. Walking and focused sensation
v. Yoga (homework)
Session 3: Acceptance, holding, allowing; and
letting be
Rationale:
a. Relating differently involves bringing to the
experience a sense of allowing it to be as it is,
without judging it or trying to make it
different; and
b. An accepting attitude is a major part of taking
care of oneself and seeing clearly what, if
anything, needs to change
• Allowing and accepting attitude towards
the illness and its symptoms
• Awareness of and opening up troubles in
the mind; expanded breathing and
stress-holding space
i. Exercise on awareness of breath, body,
thoughts and emotions
ii. Recognizing and discussing difﬁculties with
such awareness
iii. Expanded breathing space – opening up
troubles in the mind and settling down
these troubles
iv. Mindful walking
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Table 1 (cont.)
Phase Component Goals or rationale Main topics/themes Practice
3. Empowerment of self-control
of psychotic symptoms and
negative thoughts (one session)
a. Negative thoughts and moods that
accompany them colour or reduce our ability
to relate to experiences;
b. Thoughts are merely thoughts, we can choose
whether to engage with them or not; and
c. The same patterns of thoughts recur again
and again, without necessarily having to
question them and seek alternatives
• Thoughts are not facts – alternative
perspectives of seeing your thoughts and
sensations
• Options for working with negative and
disorganized thoughts
• Recognizing the recurring thoughts and
standing back from them, without
questioning them
i. Expanded breathing space
ii. Alternative perspectives and options for
working with thoughts
iii. Diary writing and awareness of early
warning signs of relapse
iv. Selection of practices (homework)
II. 1. Knowledge of schizophrenia
and its care (two sessions)
a. Understanding psychotic symptoms and
individual psychosocial health concerns;
b. Understanding cultural issues within family
and society; and
c. Identifying important needs for patients, self
and family
• Patients’ individual health needs in
relation to schizophrenia care
• Information sharing of schizophrenia
and its treatment
• Sharing of behavioural and perceptual
problems, intense emotions, and feelings
about illness management
• Discussing ways to deal with negative
thoughts and emotions, cultural issues
and beliefs of mental illness, stigma and
family
• Information about medication and its
effects, self-care, daily activities and
functioning, and illness and home
management
i. Group discussion and video watching
ii. Information search from Internet and health
care organizations
iii. Expert (both ex-patients and professionals)
sharing
iv. Selection of mindfulness practices learned
(homework)
v. Communication and social skills training
2. Illness management and
problem solving (one session)
a. Information about self-management of
schizophrenia and its related behavioural
problems; and
b. Learning effective coping and
problem-solving skills
• Enhancing social support, stress coping
and problem-solving skills by working
on each member’s life situations
• Performing behavioural rehearsals of
social interactions with co-patients (and
invited family members) within groups
• Review of real-life practice of coping
skills learned in group sessions
i. Group discussion and video watching
ii. Ex-patients’ sharing of illness management
experiences
iii. Role play on coping and problem-solving
skills
iv. Practices of coping skills learned
(homework)
III. 1. Behavioural rehearsal of
relapse prevention (two
sessions)
Session 1: How can I best take care of myself?
Rationale:
a. Speciﬁc things can be done when psychotic
symptoms threaten my living and
functioning;
• Identifying signs of relapse and
associated factors
• Reﬂect on daily activities, stressors and
accompanying emotions (i.e. nourishing
v. depleting activities)
i. Group discussion
ii. Role play and behavioural rehearsals of
coping skills and self-reﬂection
iii. Awareness of breath, body, sounds,
thoughts, difﬁculty, and social support
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b. Taking a breathing space ﬁrst and then
deciding what action to take;
c. Each patient has his/her own unique patterns
of symptoms and relapse and thus also his/
her own prevention strategies; and
d. Group members can provide support and
help each other to plan the best self-care
• Evaluation of self-care, illness
management, coping skills and
interpersonal relationships
iv. Breathing space and selecting forms of
practice to continue
v. Continuous practice of coping skills learned
(homework)
Session 2: Using learned skills to deal with future
problems in thoughts and moods
Rationale:
a. Maintaining balance in life is helped by
regular mindfulness practice; and
b. Good intentions can be strengthened by
linking practice with positive thoughts and
reasons for taking care of oneself
• What thing(s) in our life do you value
most and what can the practice help you
with?
• Preparing for future life problems and
relapse prevention
• Consolidation of selected and practiced
coping and mindfulness skills
i. Body scan, sitting and walking mindfulness
ii. Best wishing and positive thinking
iii. Group discussion about future problems
iv. Continuous practice of selected mindfulness
strategies (homework)
2. Community resources and
future plans (one session)
a. Being familiar with community support
services and resources for schizophrenia care;
b. Review of main issues and those skills
learned and selected for practices; and
c. Planning for future independent living
• Summary of the main issues and topics
covered and knowledge and skills
learned
• Introduction of available community
support resources
• Issues expected in future life and
psychological and behavioural
preparations for the future
• Action plans for illness management and
the future
• Questions and comments from group
members and speciﬁc requests for
follow-up
i. Body scan and mindful walking
ii. Discussion about learning from the
programme and plan for the future
iii. Checking each person’s support resources/
mechanisms
iv. Invitation to outcome assessment and
interviews
MBPEG, Mindfulness-based psychoeducation group programme.
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(four sessions, mainly concerning basic information
about schizophrenia and related behaviours, uncover-
ing common stressful situations, and exploring effect-
ive coping strategies); problem-solving training to
help prevent relapse (four sessions); and review on
their learned knowledge and skills and preparing for
the future (two sessions).
All group sessions of MBPEG and CPEG were
audio-recorded and progress monitoring of the two
programmes was made between group sessions by
reviewing all audiotapes. Fidelity to treatment was
assessed with a checklist as suggested by the NIH
Behavior Change Consortium recommendations
(Bellg et al. 2004). A researcher scored each recording
using the checklist. The ﬁdelity scores ranged from
90.2 to 95.2% with a mean of 92.8% for the MBPEG
run by the six advanced practice nurses and from
90.0 to 94.0% for the CPEG run by the three psychiatric
nurses. There were no signiﬁcant differences found on
the ﬁdelity scores between the therapists (p values
>0.10) and the six clinics under study (p = 0.18) using
the Kruskal–Wallis test.
TAU consisted of routine psychiatric out-patient ser-
vices received by the participants (n = 114), which were
similar across the six clinics. These services primarily
consisted of regular appointments (every 4 to 6
weeks) with psychiatrists. The TAU also involved con-
tacts with nursing staff (monthly; after medical con-
sultation) where nursing advice and brief education
were given about the illness/treatments and commu-
nity mental healthcare services. Whenever necessary,
social welfare and ﬁnance assistance was offered by
medical social workers and psychological treatment
was provided by clinical psychologists. Other struc-
tured psychological interventions received during the
study period were reported by the participants and
counter-checked with the out-patient records of the
clinics; however, there was not any MBI used in TAU.
Outcomes
Outcome assessments were conducted at participant
recruitment and at 1 week and 6, 12 and 24 months
post-treatment by research nurses (one in each country,
trained in the use of the measures) who were blind to
the group/intervention assignment. The primary out-
come measures were average number and length
of re-hospitalizations over the previous 6 months
and the 30-item PANSS (Kay et al. 1987). Complete
remission was deﬁned as 4-month simultaneous
ratings of all individual items in PANSS as score 43
(Andreasen et al. 2005).
Secondary outcomes included level of functioning as
measured by the Speciﬁc Level of Functioning Scale
(SLOF) (Schneider & Struening, 1983) and insight
into illness/treatment (Insight and Treatment
Attitudes Questionnaire; ITAQ) (McEvoy et al. 1989).
These scales were validated Chinese versions (Chan
et al. 2009; Chien & Thompson, 2014; Chien &
Bressington, 2015). Patients’ demographic, clinical
and treatment-related data were also collected at base-
line. Dosages of antipsychotics were converted into
haloperidol equivalents for comparison.
Statistical analyses
Sample size was calculated based on the results of earl-
ier trials of psychoeducation for Chinese patients with
schizophrenia, where the primary outcomes were
symptom severity and re-hospitalization rate (Chan
et al. 2009; Chien & Lee, 2013). Study power calculation
showed that 342 subjects (n = 114 per group) were
required to identify any statistically signiﬁcant differ-
ences on re-hospitalization rate and mental state
between three groups (particularly between two psy-
choeducation groups) at an average effect size of
0.25, p = 0.05 and power of 0.80, and accounting for a
potential attrition rate of 25%.
Based on the intention-to-treat principle, all analyses
were carried out using IBM’s SPSS version 20.0
(USA). Adequacy of randomization was assessed by
between-group and between-country comparisons of
baseline sociodemographic data and outcome mea-
sures (PANSS, SLOF, ITAQ, and re-hospitalization
and symptom remission rates), using χ2 tests for
dichotomous variables, and Kruskal–Wallis statistics
and analysis of variance (ANOVA) tests for ordinal
and interval data, respectively. Ensuring no violations
of assumptions of normality, linearity and homogen-
eity of variance–covariance, and multi-collinearity, a
mixed-model multivariate ANOVA (MANOVA) test
was performed for the dependent (outcome) variables
to determine whether the interventions produced the
within-between group and interactive group × time
effects hypothesized, followed by univariate analyses
(repeated-measures ANOVA tests) of the variables if
the MANOVA test results were found to be signiﬁcant.
Helmert contrasts codes were set to test any signiﬁcant
between-group differences on those measures with
signiﬁcant results in the ANOVA tests. Within-group
differences of the MBPEG participants between six
clinics, three countries and low (<6 sessions) and high
(56 sessions) attendees were examined on those out-
comes with signiﬁcant results in MANOVA and
repeated-measures ANOVA tests.
Complete remissions as the categorical outcome
measures were presented as conditional odd ratios
(ORs) and were best ﬁtted by a logistic proportional
odds random intercepts and slopes model. Mixed-effects
multilevel models were used to analyse the overall
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signiﬁcance of themodel (Wald χ2 statistic) andmodelled
(intention-to-treat) group differences on remission rates
at 24-month follow-up (i.e. whether MBPEG and/or
CPEG plus TAU was better or worse than TAU alone at
the last follow-up time-point). With only a few missing
data over the 24-month follow-ups, the last data were
brought forward for data imputation. The level of statis-
tical signiﬁcance was set at 0.05, except the univariate
ANOVA tests at 0.01 (i.e. Bonferroni’s correction of α
level).
Ethical standards
All procedures contributing to this work comply with
the ethical standards of the relevant national and institu-
tional committees on human experimentation and with
the Helsinki Declaration of 1975, as revised in 2008.
Results
Recruitment took place between 1 October 2013 and 30
April 2014 and all follow-up assessments were com-
pleted by a research assistant who was blind to subject
recruitment and intervention assignment. Of the 300
(30%) patients screened for eligibility in each country,
240 (80% in Hong Kong), 210 (70% in China) and 208
(69% in Taiwan) were found eligible and agreed to par-
ticipate. About 30–35 patients in each country (12–
17%) were approached but refused to participate,
mainly due to lack of interest in the study or pro-
gramme participation (n = 13–15), reluctance to talk
about the illness (n = 10–12) and/or having concerns
about time inconvenience for attending the interven-
tion (n = 7–11). There were 35, 36 and 40 patients in
the three countries who, after screening, withdrew
from participating in this study and their demographic
and clinical characteristics did not show signiﬁcant dif-
ference from those of the participants in this study.
Table 2 summarizes the demographic and clinical char-
acteristics of the 342patients in the three studygroups (n
= 114 in each group) and the non-participants (n = 388)
who were eligible but not selected in the study. There
were no signiﬁcant differences in sociodemographic
characteristics or antipsychotic medications between
the study groups and the non-participants at baseline.
The study procedure and patient ﬂow are presented
in Fig. 1. Attritions over the 6-month treatment and
2-year follow-up periods were relatively low at 16–
17% in the three study groups. Two CPEG participants
during the follow-up period and one in the TAU group
during the treatment period died due to chronic
medical diseases, which were found unrelated to the
interventions used. There were also no reported or
observed adverse effects of the interventions. There
were 10 and 13 participants who attended <6 (<50%)
group sessions of the MBPEG and CPEG, respectively.
Only limited amounts of data were missing across all
measurements, with 2% of primary and 5% of second-
ary outcomes not being available. There was no differ-
ence in the distribution of item/measure completion
between groups (χ2 = 1.50, degrees of freedom = 2, p =
0.23). The three groups, and three countries under
study, did not differ signiﬁcantly on any baseline
mean scores of the outcome variables and indicating
minimal covariate effects.
Results of Box’s and Levene’s tests indicated no vio-
lations of the assumptions of homogeneity of variance–
covariance matrices (p = 0.18) and equality of variances
of the outcome variables between groups (p = 0.25),
respectively. There were also few outliers, satisfactory
multivariate normality and moderate correlations
between the outcome measures (r = 0.20–0.46), sup-
porting the use of the MANOVA test to compare the
outcome scores between groups across the ﬁve assess-
ment points (times 1–5). Results of mixed-model
MANOVA indicated a signiﬁcant interactive (group x
time) treatment effect or a statistically signiﬁcant differ-
ence between the three study groups (F5,340 = 8.95, p =
0.0005; Wilks’ λ = 0.98, partial η2 = 0.34). When the
results (between-group effects) for each of the outcome
variables were considered separately (as shown in
Table 3), the three groups indicated a signiﬁcant differ-
ence on reduction in PANSS score (p = 0.003) and aver-
age length/duration of re-hospitalizations (p = 0.005),
and improvement in level of functioning (SLOF score,
p = 0.002) and insight into the illness/treatment (ITAQ
score, p = 0.0008), using a Bonferroni’s adjusted α of
0.01. An analysis of the adjusted mean scores at
times 1–5 indicated that the MBPEG participants
reported better progressive improvements in their
length of re-hospitalizations (p = 0.05), symptom sever-
ity (p = 0.01), insight into illness/treatment (p = 0.005)
and functioning (p = 0.01) than those in the CPEG.
The TAU group reported progressive mild to moderate
deteriorations in most of the outcome scores over the
24-month follow-up. Statistically signiﬁcant differences
were also found on the three SLOF subscales scores
(self-maintenance, social functioning and community
living skills; p = 0.002–0.005), and PANSS (positive and
negative symptoms; p = 0.003 and 0.01, respectively)
between the three groups across the follow-up period.
The Helmert’s contrasts tests indicated that the mean
differences of the following outcomes between the
MBPEG and the psychoeducation or routine-care group
between two timepointswere signiﬁcant at 0.05 and con-
tributed to the overall multivariate signiﬁcance:
(a) Average length of re-hospitalizations in the
MBPEG was signiﬁcantly greater reduced from
times 1 to 4, whereas it was slightly reduced in
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Table 2. Baseline sociodemographic and clinical characteristics of the MBPEG, conventional psychoeducation and usual-care groups and the non-participants
Characteristics MBPEG (n = 114) CPEG (n = 114) TAU (n = 114) Non-participants (n = 316) Test valuea p
Gender, n (%) 1.50 0.22
Male 72 (63.2) 70 (61.4) 74 (64.9) 190 (60.1)
Female 42 (36.8) 44 (38.6) 40 (35.1) 126 (39.9)
Mean age, years (S.D.) 25.1 (6.8) 25.8 (7.9) 26.0 (8.5) 25.9 (12.8) 1.92 0.11
18–29, n (%) 38 (33.3) 37 (32.5) 36 (31.6) 112 (35.4)
30–39, n (%) 44 (38.6) 42 (36.8) 48 (42.1) 110 (34.8)
40–49, n (%) 32 (28.1) 35 (30.7) 30 (26.3) 94 (29.8)
Education level, n (%) 1.89 0.14
Primary school or below 26 (22.8) 28 (24.6) 23 (20.2) 80 (25.3)
Secondary school 68 (59.7) 65 (57.0) 70 (61.4) 185 (58.6)
University or above 20 (17.5) 21 (18.4) 21 (18.4) 51 (16.1)
Primary diagnosis, n (%) 1.21 0.20
Schizophrenia 61 (53.5) 58 (50.9) 59 (51.8) 188 (59.5)
Schizophreniform disorder 15 (13.2) 14 (12.3) 12 (10.5) 33 (10.4)
Schizo-affective disorder 25 (21.9) 26 (22.8) 27 (23.7) 61 (19.3)
Other psychotic disorders 13 (11.4) 16 (14.0) 16 (14.0) 34 (10.8)
Mean monthly household income, HKDb (S.D.) 15 130 (3781) 14 075 (4105) 14 887 (4870) 17 012 (5976) 1.90 0.12
5000–10 000, n (%) 15 (13.2) 12 (10.5) 14 (12.3) 45 (14.2)
10 001–15 000, n (%) 38 (33.3) 39 (34.2) 37 (32.5) 115 (36.4)
15 001–25 000, n (%) 36 (31.6) 37 (32.5) 38 (33.3) 110 (34.8)
25 001–35 000, n (%) 25 (21.9) 26 (22.8) 25 (21.9) 46 (14.6)
Mean duration of illness, years (S.D., range) 2.6 (2.1, 0.25–5.0) 2.5 (1.7, 0.5–4.5) 2.7 (1.9, 0.5–5.0) 2.6 (2.4, 0.25–5.0) 1.95 0.15
<1, n (%) 25 (21.9) 21 (18.4) 20 (17.5) 71 (22.5) 1.89 0.12
1–2, n (%) 33 (28.9) 35 (30.7) 32 (28.1) 117 (37.0)
2–3, n (%) 35 (30.7) 34 (29.8) 36 (31.6) 95 (30.1)
3–5, n (%) 21 (18.4) 24 (21.1) 26 (22.8) 63 (19.9)
Number of family members living with patient, n (%)
0–1 28 (24.6) 25 (21.9) 24 (21.1) 95 (30.1) 2.01 0.10
2–3 58 (50.8) 55 (48.2) 59 (51.7) 175 (55.4)
4–5 28 (24.6) 34 (29.8) 31 (27.2) 46 (14.6)
Use of psychiatric services, n (%)
Medical consultation and treatment planning 113 (99.1) 114 (100.0) 113 (100.0) 313 (99.0) 1.40 0.22
Nursing advice on services and brief education 70 (61.4) 62 (54.4) 68 (59.7) 201 (63.6)
Social welfare and ﬁnancial advices 70 (61.4) 66 (57.9) 69 (60.5) 210 (66.5)
Individual/family counselling 30 (26.3) 29 (25.4) 30 (26.3) 79 (25.0)
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the CPEG and consistently increased in routine
care over time;
(b) Patients’ functioning in the MBPEG was signiﬁ-
cantly greater improved from times 1 to 4; and
for the CPEG, it also consistently improved over
time and differed signiﬁcantly from that of the
patients in routine care who showed a consistent
deterioration of functioning over time;
(c) Patients’ mental state in the MBPEG was also sign-
iﬁcantly greater improved from times 1 to 4; and
for the CPEG, it was improved and differed signiﬁ-
cantly from that in routine care at times 2 to 3; and
(d) Insight into illness score of the MBPEG was signiﬁ-
cantly greater enhanced from times 1 to 4 than
the other two groups, whereas for the CPEG it
increased slightly over time.
The above signiﬁcant outcomes (ITAQ, SLOF, PANSS
and length of re-hospitalizations) did not yield signiﬁ-
cant differences between the MBPEG participants in the
six clinics (F1,110 = 2.13–2.81, p = 0.15–0.28) and in groups
of patients with low (<6 sessions) and high (56 ses-
sions) attendance of the intervention (F1,105 = 2.15–3.45,
p = 0.10–0.19). Appendix table in the additional informa-
tion summarizes the mean scores and standard devia-
tions of the outcome measures of the participants in the
three study groups at the six clinics over the follow-up.
Complete remissions (4-month simultaneous ratings
of all PANSS item scores 43) were not signiﬁcantly
more likely in the MBPEG and CPEG than in the
TAU group at times 2 and 3, but signiﬁcant differences
emerged during times 4 and 5. In addition, there was a
signiﬁcant difference on remission rate at the latest
post-test between the MBPEG and CPEG [at 24
months: 38.9% v. 27.0%, χ2 = 4.1, p = 0.010, relative
risk (RR) = 1.9, 95% conﬁdence interval (CI) 0.9–3.0,
number needed to treat (NNT) = 2.0]. However, there
were no signiﬁcant differences on these rates between
the three study groups across the six clinics or three
countries (p = 0.12–0.38).
The differences on the estimated odds between the
two intervention groups, and between the MBPEG
and TAU-alone group, were signiﬁcant at 12 months
(Δ = 1.6 and 1.3, 95% CI 0.58–2.83 and 0.45–2.31, p =
0.022 and 0.039) and 24 months follow-up (Δ = 2.9
and 1.9, 95% CI 0.98–4.38 and 0.65–2.89, p = 0.001 and
0.010). Mixed-effects logistic regression indicated a
signiﬁcant differential change in proportional ORs
over the 24-month follow-up; 37 and 26% of the
MBPEG and CPEG participants, respectively, but
only 7.2% of the TAU group were in remission (χ2 =
8.9 and 8.0, p = 0.001 and 0.003, RR = 3.5 and 3.1, 95%
CI 2.0–7.2 and 1.6–6.3, NNT = 3.2 and 4.6).
There were no signiﬁcant differences in the medica-
tion dosages based on the converted haloperidolTy
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Table 3. Outcome measure scores at pre-test and four post-tests, results of MANOVA (group × time) and remission rates (n = 265)
MBPEG (n = 111) CPEG (n = 110) TAU (n = 112)
Instrument Time 1 Time 2 Time 3 Time 4 Time 5 Time 1 Time 2 Time 3 Time 4 Time 5 Time 1 Time 2 Time 3 Time 4 Time 5 F2,330
ITAQ (0–22)a 9.3 (3.1) 10.5(4.7) 13.9 (5.1) 14.3 (6.3) 17.9 (5.9) 9.5 (3.3) 9.0 (4.9) 10.5 (5.8) 9.8 (6.1) 10.1 (6.3) 9.5 (4.3) 9.0 (5.3) 9.8 (5.9) 9.0 (4.9) 8.9 (6.8) 8.98***
SLOF (43–215)a 139.1 (17.8) 158.0 (18.1) 169.2 (19.0) 177.9 (20.1) 198.1 (25.0) 137.9 (18.8) 143.8 (21.1) 146.5 (20.4) 149.9 (21.4) 156.1 (19.1) 138.8 (16.1) 136.4 (17.1) 134.9 (17.3) 130.4 (17.8) 132.1 (20.1) 6.40**
Self maintenance 42.6 (8.1) 45.8 (8.1) 49.8 (9.5) 52.3 (10.9) 57.8 (11.0) 41.8 (9.3) 43.1 (9.1) 44.7 (9.0) 44.4 (9.2) 46.2 (9.8) 41.4 (8.2) 39.4 (8.9) 37.9 (9.0) 35.4 (7.2) 36.0 (8.0) 5.83**
Social functioning 42.4 (8.5) 46.8 (9.0) 52.9 (9.7) 54.3 (11.0) 59.5 (11.5) 45.5 (9.0) 45.8 (9.0) 47.2 (8.7) 48.6 (9.2) 49.1 (10.2) 42.9 (9.1) 41.9 (9.1) 41.2 (9.0) 39.5 (8.4) 39.3 (9.1) 6.79**
Community living skills 54.1 (9.8) 65.4 (10.1) 67.9 (10.3) 71.3 (11.2) 79.8 (12.0) 51.7 (10.5) 56.9 (9.3) 54.6 (7.7) 57.8 (10.2) 60.2 (12.4) 54.0 (8.9) 55.1 (8.5) 54.8 (11.0) 55.5 (9.6) 56.9 (9.0) 7.00**
PANSS (30–210)a 80.3 (10.5) 74.8 (8.9) 71.1 (10.0) 69.9 (9.2) 64.3 (8.0) 81.0 (8.7) 82.1 (9.2) 80.7 (8.5) 79.0. (9.9) 76.5 (9.1) 81.0 (9.2) 80.9 (8.7) 85.8 (9.8) 89.0 (12.3) 89.8 (14.0) 6.07**
Positive symptoms 20.1 (6.8) 17.1 (6.5) 15.2 (7.0) 13.0 (5.0) 12.0 (4.8) 20.5 (8.0) 20.3 (7.8) 19.0 (8.1) 18.5 (6.3) 17.9 (5.9) 20.1 (8.0) 19.8 (6.7) 20.9 (8.1) 21.8 (9.1) 23.8 (10.0) 6.48**
Negative symptoms 19.9 (7.3) 17.0 (7.0) 18.0 (6.2) 18.5 (5.2) 19.0 (6.0) 19.5 (8.3) 19.9 (8.9) 18.9 (9.2) 19.0 (10.5) 19.1 (11.8) 20.1 (9.1) 20.8 (9.6) 21.8 (9.8) 21.3 (10.7) 22.5 (11.7) 5.10*
Re-hospitalizations
Average numberb 2.9 (1.8) 2.5 (1.5) 2.3 (2.0) 2.2 (1.5) 1.9 (1.6) 3.0 (2.0) 2.9 (1.4) 2.7 (2.0) 2.7 (1.8) 2.6 (2.0) 3.0 (1.6) 2.7 (1.6) 2.8 (2.4) 3.0 (2.2) 2.8 (2.3) 3.78
Durationc, days 19.2 (8.3) 15.6 (5.1) 13.2 (6.6) 12.0 (7.0) 10.1 (7.1) 18.9 (8.0) 17.7 (9.1) 16.2 (9.1) 17.5 (9.0) 16.1 (10.0) 19.2 (9.1) 21.8 (9.8) 20.2 (10.2) 21.0 (9.9) 21.9 (12.9) 5.23**
Remission rated, % – 9.5 15.1 29.7 38.9 – 8.9 13.0 24.8 27.0 – 6.9 8.7 9.8 7.4 –
χ2 (p)e – 1.02 (0.50) 3.0 (0.09) 4.9 (0.01) 5.9 (0.001) – 0.94 (0.55) 2.8 (0.09) 4.3 (0.03) 4.0 (0.01) – – – – – –
RRf (95% CI) – 1.3 (0.5–2.4) 1.7 (0.7–3.0) 2.5 (1.3–4.9) 2.0 (1.1–4.2) – 1.2 (0.4–0.2) 1.6 (0.6–2.8) 2.9 (1.1–4.1) 2.8 (0.7–3.1) – – – – – –
NNT – 35 9.6 5.4 3.4 – 36 10.3 6.5 5.0 – – – – – –
Data are given as mean (standard deviation) unless otherwise indicated.
MANOVA, Multivariate analysis of variance; MBPEG, mindfulness-based psychoeducation group; CPEG, conventional psychoeducation group; TAU, treatment-as-usual; time 1,
baseline measurement at the start of intervention; time 2, 1-week post-intervention; time 3, 6 months post-intervention; time 4, 12 months post-intervention; time 5, 24 months post-
intervention; ITAQ, Insight and Treatment Attitudes Questionnaire; SLOF, Speciﬁc Level of Functioning Scale; PANSS, Positive and Negative Syndrome Scale; RR, relative risk; CI,
conﬁdence interval; NNT, number needed to treat.
a Possible range of scores of each scale indicated in parentheses.
b Average number of readmissions to a psychiatric in-patient unit over the previous 6–12 months at the ﬁve measurements (times 1 to 5).
c Duration/length of readmissions to a psychiatric in-patient ward/unit in terms of average number of days of hospital stay over the previous 6 months at times 1 to 5.
d Complete remission rates deﬁned as 4-month simultaneous ratings of all PANSS item scores 43.
e χ2 Frequency between MBPEG and TAU, CPEG and TAU.
f RR using TAU as reference.
* p < 0.01, ** p < 0.005, *** p < 0.001.
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equivalents between MBPEG and CPEG groups
(F1,220 = 3.70, p = 0.10). Similarly, no signiﬁcant differ-
ences were found across the three groups in psycho-
tropic medications used and types, frequency or
hours of participation in other individual- or family-
based psychosocial interventions or psychiatric treat-
ments (Kruskal–Wallis statistics, p = 0.12–0.25).
Discussion
This is the ﬁrst international multi-centre RCT of an
MBI for people with schizophrenia. Improvements in
re-hospitalization, psychotic symptoms, functioning
and insight into the illness/treatment were comparable
between the MBPEG and CPEG at post-treatment or
short-term (6 months) follow-up, while signiﬁcant dif-
ferences between the MBPEG and the other two study
groups (the CPEG and TAU-alone group) were found
on these outcomes over 12- and 24-month follow-ups
in all three countries. Indeed, the improvements in
patient outcomes in the MBPEG were enhanced and
sustained over time, whilst the TAU-alone group dete-
riorated progressively in most patient outcomes during
the follow-up. It appears that the MBPEG with com-
bined mindfulness training and components of psy-
choeducation has indicated more sustainable and
greater beneﬁts to these patients than the conventional
psychoeducation programme alone.
The ﬁndings also indicated that there was progres-
sive enhancement of remission rates in the participants
receiving MBPEG and those receiving CPEG over the
24-month follow-up. Nevertheless, signiﬁcant greater
symptom reduction and thus complete remission
rates were observed among the participants receiving
MBPEG when compared with the other two study
groups at both 12- and 24-month follow-up. At 24-
month follow-up, more than one-third of the partici-
pants receiving MBPEG were in complete remission,
compared with about 26 and 7% of those receiving
CPEG and TAU alone, respectively.
The effect sizes observed in this study are
generally moderately large, particularly on length of
re-hospitalizations, positive symptoms, psychosocial
functioning and insight into the illness/treatment. The
short-term patient outcomes of the MBPEG demon-
strated larger effect sizes when compared with those
reported in recent literature reviews (Khoury et al.
2013), and those recommended by the US treatment
guidelines (Lehman et al. 2004). Previous studies that
indicated more signiﬁcant effects (e.g. Chadwick et al.
2009) have included small-sized samples with a
longer duration of the illness, been conducted
<12 months in a single study site, and used different
combined approaches to cognitive therapy. Further
multi-site controlled trials, involving comparative
treatments such as cognitive–behavioural therapy, cog-
nitive re-mediation and/or other insight-inducing ther-
apies, and/or shorter v. longer duration of treatment,
are recommended to establish the speciﬁcity and
superiority of the intervention and its positive effects
reported in this study.
As hypothesized, the differences on most patient
outcomes between the MBPEG and TAU-alone group
increased during the 12-month follow-up. A controlled
study of a mindfulness education group programme
has reported similar effects of symptom reduction
and increased mindful responses to stressful events
in patients with less chronic psychotic disorders imme-
diately after intervention (Langer et al. 2012). Another
single-site controlled trial of a similar mindfulness-
based psychoeducation programme in Hong Kong has
also showed a similar pattern of therapeutic gains with
Chinese people with schizophrenia at both 12- and
24-month follow-up (Chien & Thompson, 2014).
No adverse effects related to the MBI were found in
this study. Therefore, concerns previously expressed in
the literature that mindfulness and meditation training
for people with psychosis may exacerbate psychotic
symptoms (Chadwick et al. 2009; Chien & Lee, 2013)
were not supported by this study. It is also important
and interesting to note that the substantive signiﬁcant
improvements of patients could be contributed by a
combined effect of mindfulness training and psychoedu-
cation, and their core elements (e.g. self-empowerment
and regulation for illness management). Many of these
core elements can be considered potential therapeutic
components in current models of psychosocial interven-
tions (Chien et al. 2006; Chan et al. 2009). Therefore, fur-
ther research is recommended to explore the possible
beneﬁts of individual components of the MBPEG.
While this controlled trial has strong internal valid-
ity using a random sample from three countries, high
treatment ﬁdelity and moderately long follow-up, a
few main limitations should be noted. First, the partici-
pants were motivated to participate and were not blind
to the intervention allocation, which might produce an
expectation or response bias. Second, patients with a
shorter duration of schizophrenia (mean = 2.5–2.7
years), as in this study, might not be representative
of the wider schizophrenia population, those with
chronic schizophrenia, or those with co-morbidities of
other mental disorders such as substance misuse and
affective disorders (Chien & Thompson, 2014; Chien
& Bressington, 2015). Therefore, this selective sample
might have contributed to high levels of adherence to
the intervention, good attendance to intervention ses-
sions and the very low attrition rate in this study.
Third, this study was conducted by advanced practice
nurses who received intensive training from the
researchers, which may reduce its applicability into
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usual psychiatric care that tends to favour brief and
easy-to-run therapies with simple training. Lastly,
these positive patient outcomeswere generated by psy-
chiatric out-patient services in culture-speciﬁc Chinese
contexts. As mindfulness principles are traditionally
commonplace in many Asian countries it is possible
that the MBPEG intervention may be more acceptable
to patients in Chinese contexts, which may limit the
generalizability of our ﬁndings. Further multi-centre
controlled trials with psychotic patients from diverse
ethnic and sociodemographic characteristics are there-
fore recommended. Considering that schizophrenia/
psychosis is a long-term condition, future research
should also consider the longer-term beneﬁts (e.g.
over 2 years) of approaches to MBI in people with
psychosis.
Notwithstanding its limitations, this was the ﬁrst
multi-centre trial to test a mindfulness-based psychoe-
ducation programme for people with schizophrenia
over a 24-month follow-up. Compared with a conven-
tional psychoeducation group programme and usual
care alone, the patients receiving the MBPEG indicated
signiﬁcant reduction of psychotic symptoms and dur-
ation of re-hospitalizations, and improvements in func-
tioning and insight into the illness/treatment over 24
months post-intervention.
Appendix
Table: Outcome measure scores at pre-test and four post-tests for three study groups in three countries (N = 265)
MBPEG (n = 111) CPEG (n = 110) TAU (n = 112)
Hong Kong China Taiwan Hong Kong China Taiwan Hong Kong China Taiwan
Instrument M ± S.D. M ± S.D. M ± S.D. M ± S.D. M ± S.D. M ± S.D. M ± S.D. M ± S.D. M ± S.D.
ITAQ (0–22)a
Time 1 9.3 ± 3.0 9.4 ± 3.1 9.2 ± 3.0 9.3 ± 3.5 9.1 ± 3.4 9.5 ± 3.7 9.3 ± 4.0 9.2 ± 3.9 9.2 ± 4.0
Time 2 10.3 ± 4.4 10.5 ± 4.2 10.2 ± 4.9 9.2 ± 4.6 9.5 ± 3.9 9.1 ± 3.5 9.1 ± 5.0 9.0 ± 4.0 9.2 ± 4.1
Time 3 13.7 ± 5.0 13.6 ± 5.4 13.8 ± 5.9 10.3 ± 5.3 10.2 ± 5.0 10.6 ± 5.8 9.7 ± 5.1 9.8 ± 5.0 9.7 ± 4.3
Time 4 14.1 ± 6.0 14.4 ± 6.9 14.0 ± 6.5 9.9 ± 6.0 9.8 ± 5.1 10.0 ± 5.9 9.1 ± 4.0 8.9 ± 3.7 9.2 ± 3.9
Time 5 17.7 ± 5.3 17.9 ± 5.8 17.5 ± 6.5 10.2 ± 6.0 10.4 ± 6.1 10.2 ± 6.7 8.8 ± 2.9 9.0 ± 3.0 9.1 ± 4.0
SLOF (43–215)
Time 1 139.0 ± 17.1 139.1 ± 15.8 138.9 ± 17.0 137.5 ± 18.2 137.8 ± 17.4 138.2 ± 18.1 138.7 ± 16.2 138.6 ± 16.5 138.9 ± 16.2
Time 2 158.8 ± 17.0 159.1 ± 15.8 159.1 ± 14.9 143.6 ± 16.9 143.9 ± 17.8 143.8 ± 19.0 136.5 ± 16.4 136.7 ± 17.2 136.3 ± 18.1
Time 3 168.8 ± 19.8 169.1 ± 16.8 169.8 ± 18.9 146.7 ± 19.6 146.1 ± 20.0 146.8 ± 20.2 134.7 ± 17.9 134.6 ± 18.0 135.0 ± 18.2
Time 4 178.1 ± 19.8 179.1 ± 19.0 179.5 ± 17.0 149.5 ± 20.9 149.7 ± 21.0 150.3 ± 22.0 130.1 ± 18.4 130.7 ± 18.0 131.0 ± 19.2
Time 5 198.8 ± 19.8 198.0 ± 20.1 198.3 ± 20.3 156.2 ± 18.9 156.5 ± 21.2 156.0 ± 22.0 132.0 ± 18.1 131.8 ± 19.8 132.4 ± 19.1
PANSS (30–210)
Time 1 80.2 ± 10.2 80.1 ± 10.0 80.5 ± 11.2 80.8 ± 8.6 81.2 ± 8.1 81.4 ± 8.8 80.9 ± 9.1 81.3 ± 9.0 81.0 ± 8.9
Time 2 74.6 ± 9.1 74.7 ± 8.8 74.9 ± 9.3 82.0 ± 8.9 82.4 ± 9.0 82.3 ± 9.2 80.8 ± 8.9 81.2 ± 9.0 81.0 ± 8.1
Time 3 71.0 ± 9.9 70.9 ± 10.1 71.3 ± 11.2 80.6 ± 8.1 80.9 ± 9.0 81.2 ± 9.2 85.6 ± 10.0 85.9 ± 10.2 85.4 ± 8.8
Time 4 69.7 ± 9.6 70.0 ± 9.7 70.3 ± 9.8 79.2 ± 10.0 78.6 ± 9.8 79.3 ± 9.5 89.3 ± 12.0 89.1 ± 11.8 88.7 ± 10.7
Time 5 64.2 ± 8.2 64.5 ± 8.8 64.6 ± 9.0 76.4 ± 9.0 76.3 ± 9.5 76.8 ± 9.8 89.7 ± 13.9 89.9 ± 13.1 90.0 ± 14.1
SSQ6 (0–30)
Time 1 6.7 ± 2.0 6.7 ± 2.1 6.9 ± 2.2 7.0 ± 2.2 7.0 ± 2.3 7.4 ± 2.4 6.9 ± 2.6 7.1 ± 2.8 7.2 ± 2.9
Time 2 7.0 ± 2.0 6.7 ± 2.0 6.8 ± 2.1 7.0 ± 2.3 7.1 ± 2.9 7.4 ± 3.0 6.8 ± 2.9 7.0 ± 3.0 6.8 ± 3.2
Time 3 6.4 ± 2.5 6.6 ± 2.1 6.7 ± 2.5 6.7 ± 2.5 6.9 ± 2.3 7.0 ± 2.9 7.1 ± 3.4 7.2 ± 3.0 6.9 ± 3.0
Time 4 6.8 ± 2.4 6.7 ± 2.3 6.9 ± 2.8 7.0 ± 2.6 7.0 ± 2.5 7.1 ± 2.8 6.5 ± 3.0 6.9 ± 3.1 6.8 ± 3.0
Time 5 7.2 ± 2.4 7.1 ± 2.2 7.4 ± 2.3 7.1 ± 2.9 6.8 ± 3.0 6.8 ± 3.0 6.4 ± 2.2 6.7 ± 2.0 6.8 ± 2.9
Re-hospitalizations
Average Numberb
Time 1 2.8 ± 1.9 2.9 ± 2.0 2.8 ± 3.0 3.1 ± 2.1 2.9 ± 2.1 2.9 ± 2.0 3.1 ± 1.8 3.0 ± 1.9 2.9 ± 2.0
Time 2 2.4 ± 1.9 2.6 ± 2.0 2.5 ± 2.4 2.9 ± 1.8 3.0 ± 2.2 2.8 ± 2.0 2.8 ± 1.5 2.6 ± 1.9 2.8 ± 1.9
Time 3 2.2 ± 2.1 2.4 ± 2.1 2.5 ± 2.1 2.8 ± 2.1 2.6 ± 3.0 2.7 ± 2.5 2.7 ± 2.0 2.8 ± 2.0 2.6 ± 2.0
Time 4 2.1 ± 1.9 2.3 ± 2.0 2.3 ± 2.0 2.8 ± 2.0 2.7 ± 2.1 2.9 ± 2.3 3.1 ± 2.5 2.9 ± 2.8 2.8 ± 2.2
Time 5 1.8 ± 1.5 2.0 ± 1.6 2.0 ± 1.7 2.6 ± 1.9 2.8 ± 2.0 2.7 ± 2.3 2.9 ± 2.2 2.7 ± 2.7 2.6 ± 2.0
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